

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in managing axial spondyloarthritis | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-697/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-697" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in managing axial spondyloarthritis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in managing axial spondyloarthritis.">
            <meta name="og:description" content="Read the latest article version by Priyanka Agrawal, Pedro M. Machado, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24923">
            <meta name="article-id" content="22577">
            <meta name="dc.title" content="Recent advances in managing axial spondyloarthritis">
            <meta name="dc.description" content="Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA.">
            <meta name="dc.subject" content="Axial spondyloartrhitis, ankylosing spondylitis, treatment, management, biologics, outcomes.">
            <meta name="dc.creator" content="Agrawal, Priyanka">
            <meta name="dc.creator" content="Machado, Pedro M.">
            <meta name="dc.date" content="2020/07/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22577.1">
            <meta name="dc.source" content="F1000Research 2020 9:697">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Axial spondyloartrhitis">
            <meta name="prism.keyword" content="ankylosing spondylitis">
            <meta name="prism.keyword" content="treatment">
            <meta name="prism.keyword" content="management">
            <meta name="prism.keyword" content="biologics">
            <meta name="prism.keyword" content="outcomes.">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/13">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="697">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22577.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-697">
            <meta name="citation_title" content="Recent advances in managing axial spondyloarthritis">
            <meta name="citation_abstract" content="Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA.">
            <meta name="citation_description" content="Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA.">
            <meta name="citation_keywords" content="Axial spondyloartrhitis, ankylosing spondylitis, treatment, management, biologics, outcomes.">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Priyanka Agrawal">
            <meta name="citation_author_institution" content="Department of Rheumatology, Northwick Park Hospital, London North West University NHS Trust, London, UK">
            <meta name="citation_author" content="Pedro M. Machado">
            <meta name="citation_author_institution" content="Department of Rheumatology, Northwick Park Hospital, London North West University NHS Trust, London, UK">
            <meta name="citation_author_institution" content="Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK">
            <meta name="citation_author_institution" content="Centre for Rheumatology, Division of Medicine &amp; Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK">
            <meta name="citation_publication_date" content="2020/07/13">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="697">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22577.1">
            <meta name="citation_firstpage" content="697">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-697/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-697.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24923 /> <input type=hidden id=articleId name=articleId value=22577 /> <input type=hidden id=xmlUrl value="/articles/9-697/v1/xml"/> <input type=hidden id=xmlFileName value="-9-697-v1.xml"> <input type=hidden id=article_uuid value=22ce0e96-8561-4152-97f6-f7abd151eb2b /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in managing axial spondyloarthritis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22577.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22577.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-697"
  },
  "headline": "Recent advances in managing axial spondyloarthritis",
  "datePublished": "2020-07-13T11:41:01",
  "dateModified": "2020-07-13T11:41:01",
  "author": [
    {
      "@type": "Person",
      "name": "Priyanka Agrawal"
    },    {
      "@type": "Person",
      "name": "Pedro M. Machado"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-697",
            "name": "Recent advances in managing axial spondyloarthritis"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in managing axial spondyloarthritis </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24923 data-id=22577 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22577.1" data-recommended="" data-doi="10.12688/f1000research.22577.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-697/v1/pdf?article_uuid=22ce0e96-8561-4152-97f6-f7abd151eb2b" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22577-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22577-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22577-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Agrawal P and Machado PM. Recent advances in managing axial spondyloarthritis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):697 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22577.1" target=_blank>https://doi.org/10.12688/f1000research.22577.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22577-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22577 id=track-article-signin-22577 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22577?target=/articles/9-697">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24923 /> <input name=articleId type=hidden value=22577 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in managing axial spondyloarthritis</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Priyanka Agrawal<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:p.machado@ucl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Pedro M. Machado</span></a><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Priyanka Agrawal<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:p.machado@ucl.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Pedro M. Machado</span></a><sup>1-3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22577.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Rheumatology, Northwick Park Hospital, London North West University NHS Trust, London, UK<br/> <sup>2</sup> Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>3</sup> Centre for Rheumatology, Division of Medicine &amp; Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK<br/> <p> <div class=margin-bottom> Priyanka Agrawal <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Pedro M. Machado <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=71249-66605></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=71250-66604></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton. The advent of biologic drugs has transformed the management of patients with axSpA. However, non-steroidal anti-inflammatory drugs remain the first-line drug treatment for axSpA. The optimal management of patients with axSpA requires a combination of pharmacological and non-pharmacological treatment modalities, namely exercise and physical therapy. This review looks at novel therapeutic options in patients with axSpA. It also summarises current evidence regarding radiographic progression and treat-to-target in axSpA. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Axial spondyloartrhitis, ankylosing spondylitis, treatment, management, biologics, outcomes. </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Pedro M. Machado (<a href="mailto:p.machado@ucl.ac.uk">p.machado@ucl.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Pedro M. Machado </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> PMM has received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB. PA declares that she has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Agrawal P and Machado PM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Agrawal P and Machado PM. Recent advances in managing axial spondyloarthritis [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):697 (<a href="https://doi.org/10.12688/f1000research.22577.1" target=_blank>https://doi.org/10.12688/f1000research.22577.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 Jul 2020, <b>9</b>(Faculty Rev):697 (<a href="https://doi.org/10.12688/f1000research.22577.1" target=_blank>https://doi.org/10.12688/f1000research.22577.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 Jul 2020, <b>9</b>(Faculty Rev):697 (<a href="https://doi.org/10.12688/f1000research.22577.1" target=_blank>https://doi.org/10.12688/f1000research.22577.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e160>Introduction</h2><p class="" id=d13749e163>Axial spondyloarthritis (axSpA) belongs to a clinically heterogeneous group of inflammatory rheumatic diseases that share common genetic, histological, and clinical features. It encompasses ankylosing spondylitis (AS) (or radiographic axSpA [r-axSpA]) and non-radiographic axSpA (nr-axSpA)<sup><a href="#ref-1">1</a></sup>. Over the last couple of decades, we have witnessed remarkable advances in the pathogenesis, management and treatment of axSpA. The discovery of anti-tumour necrosis factor (anti-TNF) has revolutionised the treatment of this chronic condition. More recently, interleukin-17 (IL-17) has been discovered as an alternative therapeutic target and there is promise from small molecules such as Janus kinase (JAK) inhibitors<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d13749e174>In this article, we shall discuss the management of axSpA with a primary focus on the recent advances. We shall review potential new biologics on the horizon. We shall also consider the use of biosimilars, radiographic progression in axSpA and the controversy surrounding the treat-to-target (T2T) approach.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e180>Management of axial spondyloarthritis</h2><p class="" id=d13749e183>AxSpA can interfere with patients’ daily activities, including schooling, work, and social life<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. The goals of treatment are to reduce disease activity (signs and symptoms), to prevent disability and structural damage, and to maintain work productivity, health-related quality of life, and social participation<sup><a href="#ref-5">5</a></sup>. Non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy remain the mainstays of treatment of axSpA. The Assessment of Spondylarthritis International Society (ASAS) and European League Against Rheumatism (EULAR) (2016 update) recommend that patients with pain and stiffness should use an NSAID as first-line drug treatment up to the maximum dose while taking risks and benefits into account. For patients who respond well to NSAIDs, continuous use of this medication is preferred in case on-demand use results in worsening of symptoms<sup><a href="#ref-6">6</a></sup>. The 2019 American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) recommendations similarly advise that adults with active axSpA receive continuous NSAIDs over on-demand NSAIDs. However, in adults with stable axSpA, on-demand treatment with NSAIDs is recommended over continuous treatment<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d13749e205>There is controversy regarding the role of NSAIDs in preventing radiographic progression in axSpA. Slower radiographic progression was observed in AS patients taking celecoxib continuously (that is, daily) for a 2-year period, compared with patients taking it on demand, in a study by Wanders <i>et al</i>.<sup><a href="#ref-7">7</a></sup>. A post-hoc analysis of this study showed that this effect was more pronounced in patients with elevated acute-phase reactants or in patients with a high or very high Ankylosing Spondylitis Disease Activity Score (ASDAS), which includes C-reactive protein (CRP) as one of the variables<sup><a href="#ref-8">8</a></sup>. However, this inhibitory effect on new bone formation in the spine of patients with AS was not observed in a more recent randomised multicentre trial (ENRADAS) comparing continuous diclofenac intake over the course of 2 years versus on-demand treatment<sup><a href="#ref-9">9</a></sup>. Conversely, a 2-year observational study in patients with AS showed a reduction in the progression of structural damage of the spine of patients with a high NSAID intake compared with those with a low NSAID intake. This protective effect was seen nearly exclusively in patients with syndesmophytes and elevated CRP at baseline<sup><a href="#ref-10">10</a></sup>. More recently, it was suggested that continuous use of NSAIDs reduces radiographic progression in sacroiliac joints in patients with early axSpA<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d13749e232>Non-pharmacological treatment modalities are important in the management of patients with axSpA. ASAS-EULAR recommend that patients should be educated about axSpA and encouraged to exercise on a regular basis and stop smoking; physical therapy should be considered<sup><a href="#ref-6">6</a></sup>. The inclusion of aerobic components, cardiorespiratory exercises, and educational programs in traditional programs of exercises may lead to improved clinical outcomes, although the most effective exercise protocol remains unclear<sup><a href="#ref-12">12</a></sup>. Promising effects of cardiorespiratory and strength exercises on emotional distress, fatigue, and ability to do a full day’s activities were shown in a small pilot Scandinavian study in patients with axSpA<sup><a href="#ref-13">13</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e250>Biologics in the treatment of axial spondyloarthritis</h2><p class="" id=d13749e253>Until very recently there were five licensed anti-TNF drugs (adalimumab, certolizumab, etanercept, golimumab and infliximab) for the indication of AS and four (adalimumab, etanercept, certolizumab and golimumab) for the indication of nr-axSpA (in the US, only certolizumab was approved for the indication of nr-axSpA). The IL-17 blocker secukinumab has been approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the indication of AS. Ixekizumab was initially (2019) approved by the FDA for AS, and in July 2020, the FDA expanded the approval of ixekizumab to include nr-axSpA; almost simultaneously, the EMA also approved ixekizumab for the treatment of both AS and nr-axSpA.</p><p class="" id=d13749e256>ASAS-EULAR-recommended disease activity cutoffs to start anti-TNF treatment are either a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 or an ASDAS of at least 2.1 after treatment with two different NSAIDs for at least 4 weeks in total<sup><a href="#ref-6">6</a></sup>. British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology recommendations<sup><a href="#ref-14">14</a></sup> define high disease activity as BASDAI and spinal pain visual analogue scale (VAS) scores of at least 4. According to the BSR, BASDAI and VAS scores should be measured on two occasions at least 4 weeks apart and patients need to have failed two NSAIDs for at least 2 weeks each unless contraindicated.</p><p class="" id=d13749e267>The 2019 ACR-SAA-SPARTAN recommendations also advise anti-TNF drugs in patients with axSpA when activity persists despite NSAID treatment. Anti-TNF monoclonal antibodies should be preferred in patients with concomitant inflammatory bowel disease (IBD) or recurrent iritis. According to these recommendations, IL-17 blockers are advised for patients with active disease who have heart failure or demyelinating disease as a contraindication to anti-TNF and in primary non-responders to anti-TNF. Secukinumab and ixekizumab are not recommended in patients with IBD or recurrent uveitis. In the 2019 ACR-SAA-SPARTAN recommendations, tofacitinib, a JAK inhibitor currently not approved for axSpA, is highlighted as a potential second-line option for patients with contraindications to a TNF inhibitor (TNFi) other than infections. Recommendations regarding tofacitinib may change pending the results of larger clinical trials<sup><a href="#ref-5">5</a></sup>. Owing to the likelihood for symptom recurrence, discontinuation of biologics is not recommended by ACR-SAA-SPARTAN. If tapering is considered, patients should be counselled regarding the potential for increased disease activity<sup><a href="#ref-5">5</a></sup>. In <a href="#T1">Table 1</a>, an overview of biological disease-modifying anti-rheumatic drugs (DMARDs) and targeted synthetic DMARDs in axSpa and related chronic inflammatory conditions is presented.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Overview of biological disease-modifying anti-rheumatic drugs (DMARDs) and targeted synthetic DMARDs in axial spondyloarthritis and related chronic inflammatory conditions.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d13749e292 class=n-a></a><thead><a name=d13749e294 class=n-a></a><tr><a name=d13749e296 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d13749e298 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1><a name=d13749e301 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1><a name=d13749e304 class=n-a></a>Axial<br class=br>spondyloarthritis</th><th align=left colspan=1 rowspan=1><a name=d13749e309 class=n-a></a>Psoriatic<br class=br>arthritis</th><th align=left colspan=1 rowspan=1><a name=d13749e314 class=n-a></a>Psoriasis</th><th align=left colspan=1 rowspan=1><a name=d13749e318 class=n-a></a>Crohn’s<br class=br>disease</th><th align=left colspan=1 rowspan=1><a name=d13749e323 class=n-a></a>Rheumatoid<br class=br>arthritis</th><th align=left colspan=1 rowspan=1><a name=d13749e328 class=n-a></a>Uveitis</th></tr></thead><tbody><a name=d13749e333 class=n-a></a><tr><a name=d13749e335 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d13749e337 class=n-a></a><b>TNF</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e341 class=n-a></a>Adalimumab (mAb to TNF)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e344 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e346 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e348 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e351 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e353 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e355 class=n-a></a></td></tr><tr><a name=d13749e357 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e359 class=n-a></a>Certolizumab (mAb to TNF)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e362 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e364 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e366 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e368 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e371 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e373 class=n-a></a></td></tr><tr><a name=d13749e376 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e378 class=n-a></a>Etanercept (fusion protein against TNF)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e381 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e383 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e385 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e387 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e390 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e392 class=n-a></a></td></tr><tr><a name=d13749e395 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e397 class=n-a></a>Golimumab (mAb to TNF)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e400 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e402 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e404 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e406 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e409 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e411 class=n-a></a></td></tr><tr><a name=d13749e414 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e416 class=n-a></a>Infliximab (mAb to TNF)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e419 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e421 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e423 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e425 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e428 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e430 class=n-a></a></td></tr><tr><a name=d13749e434 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e436 class=n-a></a><b>IL-1</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e440 class=n-a></a>Anakinra (IL-1R antagonist)</td><td colspan=1 rowspan=1 style="background-color:#FF9900"><a name=d13749e443 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e445 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e447 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e450 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e452 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e454 class=n-a></a></td></tr><tr><a name=d13749e457 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e459 class=n-a></a><b>B cells</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e463 class=n-a></a>Rituximab (mAb to CD20)</td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e466 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e468 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e470 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e473 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e475 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e477 class=n-a></a></td></tr><tr><a name=d13749e480 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e482 class=n-a></a><b>T cells</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e486 class=n-a></a>Abatacept (inhibitor of T-cell co-<br class=br>stimulation)</td><td colspan=1 rowspan=1 style="background-color:#FF9900"><a name=d13749e491 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e493 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e495 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e498 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e500 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e502 class=n-a></a></td></tr><tr><a name=d13749e505 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d13749e507 class=n-a></a><b>IL-6</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e511 class=n-a></a>Tocilizumab (mAb to IL-6R)</td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e514 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e516 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e518 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e521 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e523 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e525 class=n-a></a></td></tr><tr><a name=d13749e528 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e530 class=n-a></a>Sarilumab (mAb to IL-6R)</td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e533 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e535 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e537 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e539 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e542 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e544 class=n-a></a></td></tr><tr><a name=d13749e547 class=n-a></a><td align=left colspan=1 rowspan=5 valign=top><a name=d13749e549 class=n-a></a><b>IL-17</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e553 class=n-a></a>Secukinumab (mAb to IL-17A)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e556 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e558 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e560 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e563 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e565 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e567 class=n-a></a></td></tr><tr><a name=d13749e570 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e572 class=n-a></a>Ixekizumab (mAb to IL-17A)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e575 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e577 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e579 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e581 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e584 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e586 class=n-a></a></td></tr><tr><a name=d13749e588 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e590 class=n-a></a>Brodalumab (mAb to IL-17R)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e593 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e595 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e597 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e599 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e602 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e604 class=n-a></a></td></tr><tr><a name=d13749e606 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e608 class=n-a></a>Bimekizumab (mAb to IL-17A and IL-17F)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e611 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e613 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e615 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e617 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e620 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e622 class=n-a></a></td></tr><tr><a name=d13749e624 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e626 class=n-a></a>Netakimab/BCD-085 (mAb to IL-17R)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e629 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e631 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e633 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e635 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e638 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e640 class=n-a></a></td></tr><tr><a name=d13749e643 class=n-a></a><td align=left colspan=1 rowspan=4 valign=top><a name=d13749e645 class=n-a></a><b>IL-12 and</b><br class=br><b>IL-23</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e652 class=n-a></a>Ustekinumab (mAb to IL-12/23p40)</td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e655 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e657 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e659 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e662 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e664 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e666 class=n-a></a></td></tr><tr><a name=d13749e669 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e671 class=n-a></a>Guselkumab (mAb to IL-23p19)</td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e674 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e676 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e678 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e680 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e683 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e685 class=n-a></a></td></tr><tr><a name=d13749e689 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e691 class=n-a></a>Tildrakizumab (mAb to IL23p19)</td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e694 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e696 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e698 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e700 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e703 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e705 class=n-a></a></td></tr><tr><a name=d13749e708 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e710 class=n-a></a>Risankizumab (mAb to IL23p19)</td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e713 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e715 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e717 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e719 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e722 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e724 class=n-a></a></td></tr><tr><a name=d13749e727 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e729 class=n-a></a><b>PDE4</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e733 class=n-a></a>Apremilast (PDE4 inhibitor)</td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e736 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e738 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e740 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e743 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e745 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e747 class=n-a></a></td></tr><tr><a name=d13749e750 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e752 class=n-a></a><b>JAK</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e756 class=n-a></a>Tofacitinib (JAK1/3 inhibitor)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e759 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e761 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e763 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e766 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e768 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e770 class=n-a></a></td></tr><tr><a name=d13749e773 class=n-a></a><td colspan=1 rowspan=1><a name=d13749e775 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e777 class=n-a></a>Filgotinib (JAK1 inhibitor)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e780 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e782 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e784 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e787 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e789 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e791 class=n-a></a></td></tr><tr><a name=d13749e794 class=n-a></a><td colspan=1 rowspan=1><a name=d13749e796 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e798 class=n-a></a>Upadacitinib (JAK1 inhibitor)</td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e801 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e803 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e805 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e808 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e810 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e812 class=n-a></a></td></tr><tr><a name=d13749e816 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e818 class=n-a></a><b>GM-CSF</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e822 class=n-a></a>Namilumab (mAB to GM-CSF)</td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e825 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e827 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e829 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e832 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e834 class=n-a></a></td><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e836 class=n-a></a></td></tr></tbody></table><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d13749e841 class=n-a></a><thead><a name=d13749e843 class=n-a></a><tr><a name=d13749e845 class=n-a></a><th align=left colspan=2 rowspan=1><a name=d13749e847 class=n-a></a>Key:</th></tr></thead><tbody><a name=d13749e852 class=n-a></a><tr><a name=d13749e854 class=n-a></a><td colspan=1 rowspan=1 style="background-color:#008000"><a name=d13749e856 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e858 class=n-a></a>Efficacy shown in at least one randomised controlled trial</td></tr><tr><a name=d13749e861 class=n-a></a><td colspan=1 rowspan=1 style="background-color:#0092C2"><a name=d13749e863 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e865 class=n-a></a>Some data from pilot or proof-of-concept trials suggest a positive effect</td></tr><tr><a name=d13749e868 class=n-a></a><td colspan=1 rowspan=1 style="background-color:#FF9900"><a name=d13749e870 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e872 class=n-a></a>Some data from pilot or proof-of-concept trials suggest a lack of effect</td></tr><tr><a name=d13749e875 class=n-a></a><td colspan=1 rowspan=1 style="background-color:#FF0000"><a name=d13749e877 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e879 class=n-a></a>Lack of efficacy shown in at least one randomised controlled trial</td></tr><tr><a name=d13749e882 class=n-a></a><td colspan=1 rowspan=1 style="background-color:#7F7F7F"><a name=d13749e884 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e886 class=n-a></a>No conclusive data available about efficacy</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d13749e893 class=n-a></a><p id=d13749e895> GM-CSF, granulocyte macrophage-colony-stimulating factor; IL, interleukin; JAK, Janus kinase; mAb, monoclonal antibody; PDE4, phosphodiesterase 4; TNF, tumour necrosis factor</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e904>Biologic drugs that have recently shown efficacy</h2><p class="" id=d13749e907>The efficacy of ixekizumab, a high-affinity monoclonal antibody (mAb) against IL-17A, has been demonstrated in both biologic-naïve and TNFi-experienced patients with r-axSpA (NCT02696785 and NCT02696798)<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup>. More recently, the first study demonstrating the efficacy of ixekizumab in nr-axSpA was also published<sup><a href="#ref-18">18</a></sup>. Positive secukinumab (NCT02696031) data in nr-axSpA were also recently presented in abstract form, but the manuscript has yet to be published<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d13749e925>Bimekizumab, a mAb that potently and selectively neutralises both IL-17A and IL-17F, has demonstrated substantial improvements in both musculoskeletal and skin outcomes<sup><a href="#ref-20">20</a></sup>. Brodalumab, a human anti-IL-17 receptor A mAb has also demonstrated efficacy in phase 3 studies in both AS and nr-axSpA<sup><a href="#ref-21">21</a></sup>. The bimekizumab and brodalumab studies have been published in abstract form only.</p><p class="" id=d13749e936>Netakimab/BCD-085, a humanised mAb against IL-17 with genetically modified Fc- and CDR-regions, has shown efficacy in active AS in a dose-finding phase 2 clinical trial (abstract publication<sup><a href="#ref-22">22</a></sup>).</p><p class="" id=d13749e943>JAK inhibitors are emerging as an effective therapeutic approach in patients with axSpA. Both tofacitinib (JAK1–3 inhibitor) and filgotinib (selective JAK1 inhibitor) have shown efficacy and safety in phase 2 placebo-controlled trials of patients with AS. Tofacitinib was superior to placebo in reducing signs, symptoms and objective endpoints of patients with active AS and had a safety profile similar to what has been reported in the literature<sup><a href="#ref-23">23</a></sup>. More recently, van der Heijde <i>et al</i>. showed that filgotinib was efficacious and safe for patients with active AS and inadequate response or intolerance to NSAIDs<sup><a href="#ref-24">24</a></sup>. Therefore, further investigation of filgotinib in AS is warranted<sup><a href="#ref-24">24</a></sup> (NCT03117270). Finally, results of the first randomised trial of upadacitinib (selective JAK1 inhibitor) versus placebo in patients with AS were recently published; upadacitinib was efficacious and well tolerated in patients with active AS who had not responded to or had a contraindication to treatment with NSAIDs. These data support further investigation of upadacitinib for the treatment of axSpA<sup><a href="#ref-25">25</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e968>Biologic drugs that have not shown efficacy</h2><p class="" id=d13749e971>Uncontrolled or controlled trials with anakinra (IL-1 blocker)<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>, abatacept (inhibitor of T-cell co-stimulation)<sup><a href="#ref-28">28</a></sup>, rituximab (B-cell depletion agent)<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup> and tocilizumab (IL-6 blocker)<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup> have shown no consistent efficacy in patients with AS. Of note, conventional synthetic DMARDs have also failed to show efficacy in axial disease.</p><p class="" id=d13749e999>Apremilast is a small-molecule inhibitor of phosphodiesterase 4 (PDE4) that modulates the inflammatory response. In a small (n = 38), 12-week, double-blind, placebo-controlled, phase 2 study of symptomatic AS patients with positive magnetic resonance imaging (MRI)<sup><a href="#ref-33">33</a></sup>, apremilast did not meet its primary endpoint (change in BASDAI score at week 12) but was associated with numerically greater improvement in all clinical assessments compared with placebo. A subsequent double-blind, placebo-controlled, phase 3 study assessing the efficacy and safety of apremilast in active AS was completed (NCT01583374). Preliminary online reports suggest that this was a negative study (primary endpoint not met: ASAS20 at week 16) (source: NCT01583374). This study has not been published yet.</p><p class="" id=d13749e1006>In a randomised, double-blind, placebo-controlled, dose-finding phase 2 study, treatment with risankizumab (a humanised mAb targeting IL-23A) did not show evidence of clinically meaningful improvements compared with placebo in patients with active AS; the primary endpoint, ASAS40 response at week 12, was not met. This study suggested that despite a genetic association with the IL-23 pathway, IL-23 may not be a relevant driver of disease pathogenesis and clinical manifestations in AS (NCT02047110)<sup><a href="#ref-34">34</a></sup>.</p><p class="" id=d13749e1013>In three placebo-controlled trials, the efficacy of ustekinumab (an anti-IL-12/23 antibody) in the treatment of axial SpA was not demonstrated. The safety profile was consistent with that of studies in other indications<sup><a href="#ref-35">35</a></sup> (NCT02437162, NCT02438787 and NCT02407223).</p><p class="" id=d13749e1021>Siebert <i>et al</i>. recently published an editorial on the reasons for failure of IL-23p19 inhibition in AS<sup><a href="#ref-36">36</a></sup>. The authors hypothesise that established AS may have “transitioned pathogenetically” to a mature type 17 phenotype, making it unresponsive to IL-23p19 blockade and other upstream treatment strategies, such as IL-6 inhibition, that would normally modulate the IL-17 response<sup><a href="#ref-36">36</a></sup>. Therefore, neutralising upstream molecules would be less effective than specifically targeting IL-17A. Furthermore, other effector pathologic pathways driving the IL-17 response are probably still unknown and need to be identified<sup><a href="#ref-36">36</a></sup>. In <a href="#T2">Table 2</a>, ongoing axSpA drug trials are presented.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Ongoing clinical trials in axial spondyloarthritis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d13749e1053 class=n-a></a><thead><a name=d13749e1055 class=n-a></a><tr><a name=d13749e1057 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d13749e1059 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d13749e1062 class=n-a></a>Mechanism of action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d13749e1065 class=n-a></a>Study design</th><th align=left colspan=1 rowspan=1 valign=top><a name=d13749e1068 class=n-a></a>Patient<br class=br>group</th><th align=left colspan=1 rowspan=1 valign=top><a name=d13749e1073 class=n-a></a>Trial number</th></tr></thead><tbody><a name=d13749e1078 class=n-a></a><tr><a name=d13749e1080 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1082 class=n-a></a>Secukinumab<br class=br>(intravenous)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1087 class=n-a></a>Human monoclonal IgG1 kappa antibody<br class=br>against IL-17</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1092 class=n-a></a>Phase 3, multicentre, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1095 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1098 class=n-a></a>NCT04156620</td></tr><tr><a name=d13749e1102 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1104 class=n-a></a>Ixekizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1107 class=n-a></a>Humanised mAb against IL-17A</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1110 class=n-a></a>Long Term Extension Study of a<br class=br>Phase 3, multicentre, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1115 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1118 class=n-a></a>NCT03129100</td></tr><tr><a name=d13749e1122 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1124 class=n-a></a>Brodalumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1127 class=n-a></a>Human mAb that binds to the IL-17<br class=br>receptor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1132 class=n-a></a>Phase 3, multicentre, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1135 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1138 class=n-a></a>NCT02985983</td></tr><tr><a name=d13749e1142 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1144 class=n-a></a>Bimekizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1147 class=n-a></a>Humanised monoclonal IgG1 antibody<br class=br>against IL-7A and IL-17F</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1152 class=n-a></a>Phase 3, multicentre, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1155 class=n-a></a>r-axSpA<br class=br>nr-axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1160 class=n-a></a>NCT03928743<br class=br>NCT03928704</td></tr><tr><a name=d13749e1166 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1168 class=n-a></a>Tildrakizumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1171 class=n-a></a>Human mAb against IL-23</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1174 class=n-a></a>Phase 3, multicentre, open label,<br class=br>non-randomised</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1179 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1182 class=n-a></a>NCT03552276</td></tr><tr><a name=d13749e1187 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1189 class=n-a></a>Netakimab/BCD-085</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1192 class=n-a></a>Humanised mAb against IL-17 with<br class=br>genetically modified Fc- and CDR-regions</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1197 class=n-a></a>Phase 3, multicentre, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1200 class=n-a></a>r-axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1203 class=n-a></a>NCT03447704</td></tr><tr><a name=d13749e1207 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1209 class=n-a></a>Upadacitinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1212 class=n-a></a>JAK1 selective inhibitor</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1215 class=n-a></a>Phase 3, DB RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1218 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1221 class=n-a></a>NCT04169373</td></tr><tr><a name=d13749e1225 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1227 class=n-a></a>Namilumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1230 class=n-a></a>Human monoclonal IgG1 kappa antibody<br class=br>against GM-CSF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1235 class=n-a></a>Phase 2a, proof-of-concept, DB<br class=br>RCT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1240 class=n-a></a>axSpA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d13749e1243 class=n-a></a>NCT03622658</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d13749e1251 class=n-a></a><p id=d13749e1253> axSpA, axial spondyloarthritis; DB RCT, Double-Blind Placebo-Controlled Randomised Clinical Trial; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; mAb, monoclonal antibody; nr-axSpA, non-radiographic axial spondyloarthritis; r-axSpA, radiographic axial spondyloarthritis</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e1263>Biosimilars</h2><p class="" id=d13749e1266>The World Health Organization has defined a “similar biotherapeutic product” (also called “biosimilar”) as a biotherapeutic product that is similar in terms of quality, safety and efficacy to an already licensed original or “reference biotherapeutic product” (also called “originator” drug)<sup><a href="#ref-37">37</a></sup>. In adults with stable AS receiving an originator anti-TNF, ACR-SAA-SPARTAN strongly recommends continuing treatment with the originator anti-TNF over mandated switching to its biosimilar<sup><a href="#ref-5">5</a></sup>. The BSR published a position statement<sup><a href="#ref-38">38</a></sup> on the use of biosimilars in clinical practice. The key principles of this document are that (1) all biologics and biosimilars should be prescribed by brand name rather than by international non-proprietary name, (2) clinical effectiveness and patient safety should be the overriding principles for prescribing any biologic agent, (3) substitution should be done only with the consent of the prescribing clinician, (4) decisions should be made in partnership with the patients, and (5) registration with the BSR Biologic Registers or other appropriate UK register is recommended. Therefore, switching should be based on a shared decision-making process between patients and rheumatologists, should be a clinically informed decision not made solely for economic reasons, and should take contextual factors of the health-care system into account<sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d13749e1285>Biosimilars are now often prescribed as the first biologic drug treatment, and many patients have been successfully switched from originator drugs to the biosimilar. They have resulted in substantial savings on the use of biologic therapy, providing greater accessibility to patients. There are now biosimilars for adalimumab (Amgevita, Cyltezo, Hyrimoz and Imraldi), etanercept (Benepali, Erelzi and Eticovo) and infliximab (Inflectra, Ixifi, Remicade, Remsima and Renflexis) and many more being produced/tested.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e1291>Role of biologics in the inhibition of radiographic progression</h2><p class="" id=d13749e1294>The clinical efficacy of biologics in axSpA has been robustly demonstrated. However, it is still unclear whether they can prevent the progression of structural damage, particularly new bone formation. There are also methodological challenges that have contributed to this uncertainty, namely the fact that radiographic progression is a slow process that requires at least 2 years in order to be reliably detected and the ethical impossibility of performing a comparative study with a 2-year placebo arm (given the known clinical efficacy of biologics in patients who do not respond to conventional treatments)<sup><a href="#ref-2">2</a></sup>.</p><p class="" id=d13749e1301>Importantly, radiographic progression is a heterogeneous process that varies significantly not only between patients but also within the same patient (bursts of radiographic progression can be followed by periods of a relatively low rate of progression or even no progression). Some risk factors for radiographic progression have been identified: the presence of syndesmophytes (the strongest risk factor; previous damage predicts further damage), male gender, HLA-B27 positivity, long disease/symptom duration, high CRP, MRI activity, high disease activity and smoking. It is hypothesised that more intensive T2T approaches might contribute to decreasing the rate of radiographic progression, particularly in high-risk groups<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d13749e1308>Karmacharya <i>et al</i>.<sup><a href="#ref-40">40</a></sup> recently undertook a systematic review and meta-analysis on the effect of different therapies on radiographic progression in axSpA and suggested a protective effect of TNFi treatment on spinal radiographic progression of AS after at least 4 years of treatment in studies with low risk of bias. Observational data therefore suggest that anti-TNF treatment might prevent new bone formation in axSpA. Regarding NSAIDs (also discussed above) and secukinumab, only data up to 2 years were available, and no effect was found.</p><p class="" id=d13749e1318>SURPASS is an ongoing trial comparing the effect of secukinumab on radiographic progression in AS as compared with an adalimumab biosimilar<sup><a href="#ref-41">41</a></sup>. The primary endpoint of this first head-to-head, phase 3b, randomised, biologic-controlled study is “the absence of progression as measured by the modified Stoke Ankylosing Spondylitis Spine Score”<sup><a href="#ref-41">41</a></sup>. Hopefully, this study will give us more information regarding the comparative structural efficacy of TNF blockers versus IL-17 blockers, thus contributing to evidence-based decision-making.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e1332>Treat-to-target approach</h2><p class="" id=d13749e1335>The concept of T2T strategies is well founded in the management of chronic diseases that have a well-defined and usually very objective measure that is highly associated with future health outcomes and evidence that maintaining the levels of this measure below a certain threshold will lead to better long-term health<sup><a href="#ref-42">42</a></sup>. The T2T approach in axSpA is indirectly supported by associations between levels of axSpA disease activity (particularly ASDAS) and future radiographic progression but lacks robust direct evidence. The 2019 ACR-SAA-SPARTAN recommendations mention that “focus on a specific target could lead to rapid cycling through all currently available treatments in some patients”<sup><a href="#ref-5">5</a></sup>. The 2016 update of the ASAS/EULAR recommendations for the management of axSpA recommends that “treatment should be guided according to a predefined treatment target” but controversy remains as to what this target should be<sup><a href="#ref-6">6</a></sup>. Importantly, this document also states that “the target should be a shared decision between patient and rheumatologist, taking all relevant situational factors into consideration”<sup><a href="#ref-6">6</a></sup>. However, data from a randomised controlled trial comparing the efficacy of a T2T approach versus standard of care in axSpA are still lacking. Furthermore, the cost effectiveness of a T2T strategy in clinical practice will require testing<sup><a href="#ref-43">43</a></sup>.</p><p class="" id=d13749e1358>The 2017 international task force update of recommendations on T2T in axSpA and psoriatic arthritis<sup><a href="#ref-44">44</a></sup> advises that the treatment target should be clinical remission/inactive disease of musculoskeletal (arthritis, dactylitis, enthesitis and axial disease) and extra-articular manifestations. In axSpA, the ASDAS is a preferred measure to define the target.</p><p class="" id=d13749e1365>The Tight Control in Spondyloarthritis (TICOSPA) study is a prospective, randomised (cluster) study to evaluate the potential benefit of a T2T approach in comparison with standard of care in patients with axSpA (TICOSPA, NCT03043846). Results from this study were presented in June at the EULAR 2020 conference (THU0370); the authors reported that usual care resulted in a good outcome in a substantial number of patients but the tight control and treat-to-target strategy was not superior for the primary outcome (ASAS Health Index) despite a greater number of bDMARDs prescription; nevertheless, a general trend in favour of the tight control arm was observed, with a comparable safety profile, and was found to be favourable from a societal health economic perspective. A German 1-year randomised controlled study taking an intense treatment approach versus routine treatment (STRIKE, NCT02897115) was prematurely terminated because of slow recruitment. Another phase 3 clinical trial, the Treat-to-target in Axial Spondyloarthritis (AScalate) study, is currently recruiting and is a randomised, open-label multicentre trial to investigate the efficacy of a T2T treatment strategy with secukinumab as a first-line biologic compared with a standard-of-care treatment over 36 weeks in patients with active axSpA (NCT03906136). A phase 4 trial, the Treat-to-target With Secukinumab in Axial Spondyloarthritis (TRACE) study, is also looking at T2T with secukinumab in axSpA (NCT03639740).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d13749e1371>Conclusions</h2><p class="" id=d13749e1374>With so many new biologics on the horizon, the future looks promising for managing patients with axSpA. However, there is an unmet need for results from head-to-head studies directly comparing the efficacy and safety of different biologics in axSpA. This would help determine the optimal sequencing of treatments. There are limitations in using disease activity scores and radiographic progression as markers of treatment response and hence research into suitable biomarkers needs to be undertaken.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d13749e1381 class=n-a></a><h2 class=main-title id=d13749e1383>Acknowledgements</h2><p class="" id=d13749e1386>PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the National Health Service (UK), the NIHR or the Department of Health (UK).</p></div><div class=back-section><a name=d13749e1390 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d14052>References</h2><div class="section ref-list"><a name=d13749e1390 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732839765"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1397 class=n-a></a>Dubash S, McGonagle D, Marzo-Ortega H: New advances in the understanding and treatment of axial spondyloarthritis: From chance to choice. <i>Ther Adv Chronic Dis.</i> 2018; <b>9</b>(3): 77–87. <a target=xrefwindow id=d13749e1405 href="http://www.ncbi.nlm.nih.gov/pubmed/29511503">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1408 href="https://doi.org/10.1177/2040622317743486">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1411 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5833172">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732839765">Faculty Opinions Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d13749e1424 class=n-a></a>Jones A, Ciurtin C, Ismajli M, <i> et al.</i>: Biologics for treating axial spondyloarthritis. <i>Expert Opin Biol Ther.</i> 2018; <b>18</b>(6): 641–52. <a target=xrefwindow id=d13749e1435 href="http://www.ncbi.nlm.nih.gov/pubmed/29681195">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1438 href="https://doi.org/10.1080/14712598.2018.1468884">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/738264709"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1447 class=n-a></a>Boonen A, Sieper J, van der Heijde D, <i> et al.</i>: The burden of non-radiographic axial spondyloarthritis. <i>Semin Arthritis Rheum.</i> 2015; <b>44</b>(5): 556–62. <a target=xrefwindow id=d13749e1458 href="http://www.ncbi.nlm.nih.gov/pubmed/25532945">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1461 href="https://doi.org/10.1016/j.semarthrit.2014.10.009">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/738264709">Faculty Opinions Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d13749e1474 class=n-a></a>Ward MM: Quality of life in patients with ankylosing spondylitis. <i>Rheum Dis Clin North Am.</i> 1998; <b>24</b>(4): 815–27. <a target=xrefwindow id=d13749e1482 href="http://www.ncbi.nlm.nih.gov/pubmed/9891712">PubMed Abstract </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736478889"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1491 class=n-a></a>Ward MM, Deodhar A, Gensler LS, <i> et al.</i>: 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. <i>Arthritis Care Res (Hoboken).</i> 2019; <b>71</b>(10): 1285–99. <a target=xrefwindow id=d13749e1502 href="http://www.ncbi.nlm.nih.gov/pubmed/31436026">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1505 href="https://doi.org/10.1002/acr.24025">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6764857">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736478889">Faculty Opinions Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727206345"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1523 class=n-a></a>van der Heijde D, Ramiro S, Landewé R, <i> et al.</i>: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(6): 978–91. <a target=xrefwindow id=d13749e1534 href="http://www.ncbi.nlm.nih.gov/pubmed/28087505">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1537 href="https://doi.org/10.1136/annrheumdis-2016-210770">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727206345">Faculty Opinions Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718524879"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1550 class=n-a></a>Wanders A, van der Heijde D, Landewé R, <i> et al.</i>: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. <i>Arthritis Rheum.</i> 2005; <b>52</b>(6): 1756–65. <a target=xrefwindow id=d13749e1561 href="http://www.ncbi.nlm.nih.gov/pubmed/15934081">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1564 href="https://doi.org/10.1002/art.21054">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718524879">Faculty Opinions Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d13749e1577 class=n-a></a>Kroon F, Landewé R, Dougados M, <i> et al.</i>: Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(10): 1623–9. <a target=xrefwindow id=d13749e1588 href="http://www.ncbi.nlm.nih.gov/pubmed/22532639">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1591 href="https://doi.org/10.1136/annrheumdis-2012-201370">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725699115"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1600 class=n-a></a>Sieper J, Listing J, Poddubnyy D, <i> et al.</i>: Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: Results from a randomised multicentre trial (ENRADAS). <i>Ann Rheum Dis.</i> 2016; <b>75</b>(8): 1438–43. <a target=xrefwindow id=d13749e1611 href="http://www.ncbi.nlm.nih.gov/pubmed/26242443">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1614 href="https://doi.org/10.1136/annrheumdis-2015-207897">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725699115">Faculty Opinions Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717964043"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1627 class=n-a></a>Poddubnyy D, Rudwaleit M, Haibel H, <i> et al.</i>: Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort. <i>Ann Rheum Dis.</i> 2012; <b>71</b>(10): 1616–22. <a target=xrefwindow id=d13749e1638 href="http://www.ncbi.nlm.nih.gov/pubmed/22459541">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1641 href="https://doi.org/10.1136/annrheumdis-2011-201252">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717964043">Faculty Opinions Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d13749e1654 class=n-a></a>Rumiantceva D, Dubinina T, Rumyantseva O, <i> et al.</i>: SAT0278 Nsaids reduces radiographic progression in sacloiliac joints in early axial spondyloarthritis. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(Suppl 2): 1003. <a target=xrefwindow id=d13749e1665 href="https://doi.org/10.1136/annrheumdis-2018-eular.1401">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736432089"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1675 class=n-a></a>Perrotta FM, Musto A, Lubrano E: New Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A Review. <i>Rheumatol Ther.</i> 2019; <b>6</b>(4): 479–86. <a target=xrefwindow id=d13749e1683 href="http://www.ncbi.nlm.nih.gov/pubmed/31410786">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1686 href="https://doi.org/10.1007/s40744-019-00170-x">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1689 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6858478">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736432089">Faculty Opinions Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/731183031"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1702 class=n-a></a>Sveaas SH, Berg IJ, Fongen C, <i> et al.</i>: High-intensity cardiorespiratory and strength exercises reduced emotional distress and fatigue in patients with axial spondyloarthritis: A randomized controlled pilot study. <i>Scand J Rheumatol.</i> 2018; <b>47</b>(2): 117–21. <a target=xrefwindow id=d13749e1713 href="http://www.ncbi.nlm.nih.gov/pubmed/28891743">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1716 href="https://doi.org/10.1080/03009742.2017.1347276">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/731183031">Faculty Opinions Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726862540"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1729 class=n-a></a>Hamilton L, Barkham N, Bhalla A, <i> et al.</i>: BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. <i>Rheumatology (Oxford).</i> 2017; <b>56</b>(2): 313–6. <a target=xrefwindow id=d13749e1740 href="http://www.ncbi.nlm.nih.gov/pubmed/27558584">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1743 href="https://doi.org/ 10.1093/rheumatology/kew223">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726862540">Faculty Opinions Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734297181"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1756 class=n-a></a>van der Heijde D, Cheng-Chung Wei J, Dougados M, <i> et al.</i>: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. <i>Lancet.</i> 2018; <b>392</b>(10163): 2441–51. <a target=xrefwindow id=d13749e1767 href="http://www.ncbi.nlm.nih.gov/pubmed/30360964">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1770 href="https://doi.org/10.1016/S0140-6736(18)31946-9">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734297181">Faculty Opinions Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734268130"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1783 class=n-a></a>Deodhar A, Poddubnyy D, Pacheco-Tena C, <i> et al.</i>: Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(4): 599–611. <a target=xrefwindow id=d13749e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/30343531">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1797 href="https://doi.org/10.1002/art.40753">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1801 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6593790">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734268130">Faculty Opinions Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736865054"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1814 class=n-a></a>Dougados M, Wei JCC, Landewé R, <i> et al.</i>: Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Ann Rheum Dis.</i> 2020; <b>79</b>(2): 176–85. <a target=xrefwindow id=d13749e1825 href="http://www.ncbi.nlm.nih.gov/pubmed/31685553">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1828 href="https://doi.org/10.1136/annrheumdis-2019-216118">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7025731">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736865054">Faculty Opinions Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737059857"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1846 class=n-a></a>Deodhar A, van der Heijde D, Gensler LS, <i> et al.</i>: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial. <i>Lancet.</i> 2020; <b>395</b>(10217): 53–64. <a target=xrefwindow id=d13749e1857 href="http://www.ncbi.nlm.nih.gov/pubmed/31813637">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1860 href="https://doi.org/10.1016/S0140-6736(19)32971-X">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737059857">Faculty Opinions Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d13749e1873 class=n-a></a>Deodhar A, Blanco R, Dokoupilova E, <i> et al.</i>: Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study [abstract]. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(suppl 10). Accessed November 26. <a target=xrefwindow id=d13749e1884 href="https://acrabstracts.org/abstract/secukinumab-150-mg-significantly-improved-signs-and-symptoms-of-non-radiographic-axial-spondyloarthritis-results-from-a-phase-3-double-blind-randomized-placebo-controlled-study/">Reference Source</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d13749e1893 class=n-a></a>Ritchlin CT, Kavanaugh A, Merola JF, <i> et al.</i>: Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active, Psa: Results from a 48-Week Phase 2b, Randomized, Double Blind, Placebo-Controlled, Dose- Ranging Study. <i>Abstr Arthritis Rheumatol.</i> 2018; <b>70</b>(suppl 1). <a target=xrefwindow id=d13749e1904 href="https://acrabstracts.org/abstract/dual-neutralization-of-il-17a-and-il-17f-with-bimekizumab-in-patients-with-active-psa-results-from-a-48-week-phase-2b-randomized-double%E2%80%91blind-placebo-controlled-dose-ranging-study/">Reference Source</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d13749e1913 class=n-a></a>Wei JCC, <i> et al.</i>: OP0234 Efficacy and safety of Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis: a 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study. In <i>Oral Presentations</i>. <i>Annals of the Rheumatic Diseases.</i>2019; <b>78</b>(Suppl 2): 195.1–195 (BMJ Publishing Group Ltd and European League Against Rheumatism). <a target=xrefwindow id=d13749e1927 href="https://doi.org/10.1136/annrheumdis-2019-eular.6888">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d13749e1936 class=n-a></a>Mazurov V, Erdes S, Kunder E, <i> et al.</i>: OP0028 Efficacy and safety of bcd-085, a novel il-17 inhibitor, in ankylosing spondylitis. results of phase 2 clinical study. <i>Annals of the Rheumatic Diseases.</i> 2018; <b>77</b>(Suppl 2): 64. <a target=xrefwindow id=d13749e1947 href="https://doi.org/10.1136/annrheumdis-2018-eular.2380">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727248402"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1956 class=n-a></a>van der Heijde D, Deodhar A, Wei JC, <i> et al.</i>: Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study. <i>Ann Rheum Dis.</i> 2017; <b>76</b>(8): 1340–7. <a target=xrefwindow id=d13749e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/28130206">PubMed Abstract </a> | <a target=xrefwindow id=d13749e1970 href="https://doi.org/10.1136/annrheumdis-2016-210322">Publisher Full Text </a> | <a target=xrefwindow id=d13749e1974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5738601">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727248402">Faculty Opinions Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734297178"><span class="faculty-opinion-icon small"></span></a><a name=d13749e1988 class=n-a></a>van der Heijde D, Baraliakos X, Gensler LS, <i> et al.</i>: Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet.</i> 2018; <b>392</b>(10162): 2378–87. <a target=xrefwindow id=d13749e1999 href="http://www.ncbi.nlm.nih.gov/pubmed/30360970">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2002 href="https://doi.org/10.1016/S0140-6736(18)32463-2">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734297178">Faculty Opinions Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736899531"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2015 class=n-a></a>van der Heijde D, Song IH, Pangan AL, <i> et al.</i>: Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. <i>Lancet.</i> 2019; <b>394</b>(10214): 2108–17. <a target=xrefwindow id=d13749e2026 href="http://www.ncbi.nlm.nih.gov/pubmed/31732180">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2029 href="https://doi.org/10.1016/S0140-6736(19)32534-6">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736899531">Faculty Opinions Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d13749e2042 class=n-a></a>Tan AL, Marzo-Ortega H, O'Connor P, <i> et al.</i>: Efficacy of anakinra in active ankylosing spondylitis: A clinical and magnetic resonance imaging study. <i>Ann Rheum Dis.</i> 2004; <b>63</b>(9): 1041–5. <a target=xrefwindow id=d13749e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/15066864">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2056 href="https://doi.org/10.1136/ard.2004.020800">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2060 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1755137">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d13749e2069 class=n-a></a>Haibel H, Rudwaleit M, Listing J, <i> et al.</i>: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. <i>Ann Rheum Dis.</i> 2005; <b>64</b>(2): 296–8. <a target=xrefwindow id=d13749e2080 href="http://www.ncbi.nlm.nih.gov/pubmed/15208175">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2083 href="https://doi.org/10.1136/ard.2004.023176">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2087 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1755331">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d13749e2096 class=n-a></a>Song IH, Heldmann F, Rudwaleit M, <i> et al.</i>: Treatment of active ankylosing spondylitis with abatacept: An open-label, 24-week pilot study. <i>Ann Rheum Dis.</i> 2011; <b>70</b>(6): 1108–10. <a target=xrefwindow id=d13749e2107 href="http://www.ncbi.nlm.nih.gov/pubmed/21415053">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2110 href="https://doi.org/10.1136/ard.2010.145946">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718524885"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2119 class=n-a></a>Song IH, Heldmann F, Rudwaleit M, <i> et al.</i>: Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. <i>Arthritis Rheum.</i> 2010; <b>62</b>(5): 1290–7. <a target=xrefwindow id=d13749e2130 href="http://www.ncbi.nlm.nih.gov/pubmed/20461780">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2133 href="https://doi.org/10.1002/art.27383">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718524885">Faculty Opinions Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718524886"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2147 class=n-a></a>Song IH, Heldmann F, Rudwaleit M, <i> et al.</i>: One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(2): 305–6. <a target=xrefwindow id=d13749e2158 href="http://www.ncbi.nlm.nih.gov/pubmed/22887847">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2161 href="https://doi.org/10.1136/annrheumdis-2012-201926">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718524886">Faculty Opinions Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718019518"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2174 class=n-a></a>Sieper J, Porter-Brown B, Thompson L, <i> et al.</i>: Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: Results of randomised, placebo-controlled trials. <i>Ann Rheum Dis.</i> 2014; <b>73</b>(1): 95–100. <a target=xrefwindow id=d13749e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/23765873">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2188 href="https://doi.org/10.1136/annrheumdis-2013-203559">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3888605">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718019518">Faculty Opinions Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718281811"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2205 class=n-a></a>Sieper J, Braun J, Kay J, <i> et al.</i>: Sarilumab for the treatment of ankylosing spondylitis: Results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Ann Rheum Dis.</i> 2015; <b>74</b>(6): 1051–7. <a target=xrefwindow id=d13749e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/24550171">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2219 href="https://doi.org/10.1136/annrheumdis-2013-204963">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2223 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4431338">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718281811">Faculty Opinions Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/717958700"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2236 class=n-a></a>Pathan E, Abraham S, van Rossen E, <i> et al.</i>: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. <i>Ann Rheum Dis.</i> 2013; <b>72</b>(9): 1475–80. <a target=xrefwindow id=d13749e2247 href="http://www.ncbi.nlm.nih.gov/pubmed/22984171">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2250 href="https://doi.org/10.1136/annrheumdis-2012-201915">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/717958700">Faculty Opinions Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733519001"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2263 class=n-a></a>Baeten D, Østergaard M, Wei JCC, <i> et al.</i>: Risankizumab, an IL-23 Inhibitor, for Ankylosing Spondylitis: Results of a Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept, Dose-Finding Phase 2 Study. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(9): 1295–302. <a target=xrefwindow id=d13749e2274 href="http://www.ncbi.nlm.nih.gov/pubmed/29945918">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2277 href="https://doi.org/10.1136/annrheumdis-2018-213328">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2281 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6104676">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733519001">Faculty Opinions Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734035996"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2294 class=n-a></a>Deodhar A, Gensler LS, Sieper J, <i> et al.</i>: Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis Rheumatol.</i> 2019; <b>71</b>(2): 258–70. <a target=xrefwindow id=d13749e2305 href="http://www.ncbi.nlm.nih.gov/pubmed/30225992">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2308 href="https://doi.org/10.1002/art.40728">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734035996">Faculty Opinions Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734206102"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2322 class=n-a></a>Siebert S, Millar NL, McInnes IB: Why Did IL-23p19 Inhibition Fail in AS: A Tale of Tissues, Trials or Translation? <i>Ann Rheum Dis.</i> 2019; <b>78</b>(8): 1015–8. <a target=xrefwindow id=d13749e2330 href="http://www.ncbi.nlm.nih.gov/pubmed/30297330">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2333 href="https://doi.org/10.1136/annrheumdis-2018-213654">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2336 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6691857">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734206102">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d13749e2349 class=n-a></a>Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs): WHO Expert Committee on Biological Standardization, Sixtieth report (19-23 October 2009). WHO Technical Report Series No. 977, 2013 - Annex 2. <a target=xrefwindow id=d13749e2351 href="https://www.who.int/biologicals/expert_committee/TRS_977_60th_report.pdf?ua=1">Reference Source</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d13749e2360 class=n-a></a>January 2017 Position statement: biosimilar medicines. <a target=xrefwindow id=d13749e2362 href="https://www.rheumatology.org.uk/Portals/0/Policy/PolicyStatements/Biosimilars.pdf">Reference Source</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/730526800"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2371 class=n-a></a>Kay J, Schoels MM, Dörner T, <i> et al.</i>: Consensus-based Recommendations for the Use of Biosimilars to Treat Rheumatological Diseases. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(2): 165–74. <a target=xrefwindow id=d13749e2382 href="http://www.ncbi.nlm.nih.gov/pubmed/28866648">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2385 href="https://doi.org/10.1136/annrheumdis-2017-211937">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/730526800">Faculty Opinions Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737245439"><span class="faculty-opinion-icon small"></span></a><a name=d13749e2398 class=n-a></a>Karmacharya P, Duarte-Garcia A, Dubreuil M, <i> et al.</i>: Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Rheumatol.</i> 2020; <b>72</b>(5): 733–49. <a target=xrefwindow id=d13749e2409 href="http://www.ncbi.nlm.nih.gov/pubmed/31960614">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2412 href="https://doi.org/10.1002/art.41206">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2416 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7218689">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737245439">Faculty Opinions Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d13749e2429 class=n-a></a>Baraliakos X, Østergaard M, Gensler LS, <i> et al.</i>: Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients With Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). <i>Clin Drug Investig.</i> 2020; <b>40</b>(3): 269–78. <a target=xrefwindow id=d13749e2440 href="http://www.ncbi.nlm.nih.gov/pubmed/31983056">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2443 href="https://doi.org/10.1007/s40261-020-00886-7">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d13749e2453 class=n-a></a>Atar D, Birkeland KI, Uhlig T: 'Treat to Target': Moving Targets From Hypertension, Hyperlipidaemia and Diabetes to Rheumatoid Arthritis. <i>Ann Rheum Dis.</i> 2010; <b>69</b>(4): 629–30. <a target=xrefwindow id=d13749e2461 href="http://www.ncbi.nlm.nih.gov/pubmed/20237122">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2464 href="https://doi.org/10.1136/ard.2010.128462">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d13749e2473 class=n-a></a>Machado PM, Deodhar A: Treat-to-target in Axial Spondyloarthritis: Gold Standard or Fools' Gold? <i>Curr Opin Rheumatol.</i> 2019; <b>31</b>(4): 344–8. <a target=xrefwindow id=d13749e2481 href="http://www.ncbi.nlm.nih.gov/pubmed/31090589">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2484 href="https://doi.org/10.1097/BOR.0000000000000625">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d13749e2493 class=n-a></a>Smolen JS, Schöls M, Braun J, <i> et al.</i>: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Ann Rheum Dis.</i> 2018; <b>77</b>(1): 3–17. <a target=xrefwindow id=d13749e2504 href="http://www.ncbi.nlm.nih.gov/pubmed/28684559">PubMed Abstract </a> | <a target=xrefwindow id=d13749e2507 href="https://doi.org/10.1136/annrheumdis-2017-211734">Publisher Full Text </a> | <a target=xrefwindow id=d13749e2511 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5754738">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-697&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-697&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Rheumatology, Northwick Park Hospital, London North West University NHS Trust, London, UK<br/> <sup>2</sup> Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK<br/> <sup>3</sup> Centre for Rheumatology, Division of Medicine &amp; Department of Neuromuscular Diseases, Institute of Neurology, University College London, London, UK<br/> <p> <div class=margin-bottom> Priyanka Agrawal <br/> <span>Roles: </span> Writing – Original Draft Preparation </div> <div class=margin-bottom> Pedro M. Machado <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-697/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 Jul 2020, 9:697 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22577.1">https://doi.org/10.12688/f1000research.22577.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Agrawal P and Machado PM. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24923 data-id=22577 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22577.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-697/v1/pdf?article_uuid=22ce0e96-8561-4152-97f6-f7abd151eb2b" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22577.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Agrawal P and Machado PM. Recent advances in managing axial spondyloarthritis [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):697 (<a href="https://doi.org/10.12688/f1000research.22577.1" target=_blank>https://doi.org/10.12688/f1000research.22577.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22577 id=mobile-track-article-signin-22577 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22577?target=/articles/9-697"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24923 /> <input name=articleId type=hidden value=22577 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Daniel Wendling</strong>, Department of Rheumatology, CHRU Besançon, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Peter Cheung</strong>, Division of Rheumatology, National University Hospital, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-697&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-697&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=71249-66605></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=71250-66604></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-697/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 Jul 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Daniel Wendling</strong>, Department of Rheumatology, CHRU Besançon, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter Cheung</strong>, Division of Rheumatology, National University Hospital, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-697&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-697/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in managing axial spondyloarthritis".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-697/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-697/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-697/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Agrawal P and Machado PM');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-697/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-697",
            templates : {
                twitter : "Recent advances in managing axial spondyloarthritis. Agrawal P and Machado PM, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-697/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in managing axial spondyloarthritis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in managing axial spondyloarthritis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22577/24923")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24923");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "66605": 1,
                           "66604": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "8a04b43f-0c36-44f8-8297-8a2fb781ff7b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-697.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-697.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-697.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-697.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-697.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>